{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:35:30Z","timestamp":1791858930932,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtct.2026.04.026","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T23:43:27Z","timestamp":1777074207000},"page":"887.e1-887.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Eculizumab for Pediatric Hematopoietic Cell Transplant\u2013Associated Thrombotic Microangiopathy: Real-World Response Rates, Predictors of Poor Response, and an Optimal Time Point for Treatment Response Assessment"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4565-6399","authenticated-orcid":false,"given":"Michelle L.","family":"Schoettler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6929-2502","authenticated-orcid":false,"given":"Geoffrey","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4618-3813","authenticated-orcid":false,"given":"Christine S.","family":"Higham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6146-3952","authenticated-orcid":false,"given":"Christopher C.","family":"Dvorak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Rush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3371-2920","authenticated-orcid":false,"given":"Hemalatha G.","family":"Rangarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6794-0860","authenticated-orcid":false,"given":"Majed","family":"Al-Nazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Polishchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Chaudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2090-4897","authenticated-orcid":false,"given":"Christine","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9778-1197","authenticated-orcid":false,"given":"Miki","family":"Nishitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haig","family":"Manougian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Rotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Ofori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Orbodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2723-2570","authenticated-orcid":false,"given":"Ellen","family":"Kenney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satheesh","family":"Chonat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5554-5890","authenticated-orcid":false,"given":"Joseph","family":"Chewning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5767-4396","authenticated-orcid":false,"given":"Caitlin","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9309-6205","authenticated-orcid":false,"given":"Adrianna","family":"Westbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten M.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2026.04.026_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/bloodadvances.2020003455","article-title":"A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant","volume":"5","author":"Dandoy","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.026_bib0002","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ajh.27186","article-title":"D-dimer and sinusoidal obstructive syndrome-novel poor prognostic features of thrombotic microangiopathy in children after hematopoietic cellular therapy in a single institution prospective cohort study","volume":"99","author":"Schoettler","year":"2024","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.026_bib0003","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.04.026_bib0004","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025028390","article-title":"High incidence of severe TA-TMA increases mortality in adult allogeneic transplant recipients: a prospective MIDAS Consortium study","author":"Vasu","year":"2025","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.026_bib0005","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41409-018-0159-8","article-title":"High-dose Carboplatin\/Etoposide\/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma","volume":"53","author":"Jodele","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.026_bib0006","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.1016\/j.bbmt.2009.12.158","article-title":"Transplant associated-thrombotic microangiopathy (TA-TMA) in pediatric neuroblastoma (NB) patients undergoing autologous stem cell transplantation (ASCT): a case-control study identifying early clinical markers of disease","volume":"16","author":"Laskin","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.04.026_bib0007","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fped.2019.00133","article-title":"Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management","volume":"7","author":"Dvorak","year":"2019","journal-title":"Front Pediatr"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.026_bib0008","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"issue":"Suppl 4","key":"10.1016\/j.jtct.2026.04.026_bib0009","first-page":"S57","article-title":"Reeling in complement in transplant-associated thrombotic microangiopathy: you're going to need a bigger boat","volume":"98","author":"Jodele","year":"2023","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.026_bib0010","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/sj.bmt.1704513","article-title":"Thrombotic microangiopathy after allogeneic bone marrow transplantation: a pathologic abnormality associated with diverse clinical syndromes","volume":"33","author":"George","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.026_bib0011","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41409-018-0293-3","article-title":"High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease","volume":"54","author":"Kraft","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.026_bib0012","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1182\/bloodadvances.2019001242","article-title":"Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort","volume":"4","author":"Schoettler","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.026_bib0013","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbmt.2012.10.006","article-title":"Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus\/sirolimus-based graft-versus-host disease prophylaxis","volume":"19","author":"Shayani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.026_bib0014","doi-asserted-by":"crossref","first-page":"282.e1","DOI":"10.1016\/j.jtct.2022.12.023","article-title":"Systematic review of signs and symptoms associated with hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"29","author":"Dandoy","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.026_bib0015","doi-asserted-by":"crossref","first-page":"392.e1","DOI":"10.1016\/j.jtct.2022.04.019","article-title":"Transplantation-associated thrombotic microangiopathy risk stratification: is there a window of opportunity to improve outcomes?","volume":"28","author":"Jodele","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.026_bib0016","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood-2017-05-782870","article-title":"Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD","volume":"130","author":"Gloude","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.04.026_bib0017","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in Thrombotic Microangiopathies: Unraveling Ariadne's thread into the labyrinth of complement therapeutics","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.026_bib0018","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1055\/s-0039-1692721","article-title":"Linking complement activation, coagulation, and neutrophils in transplant-associated thrombotic microangiopathy","volume":"119","author":"Gavriilaki","year":"2019","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.026_bib0019","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/bloodadvances.2020001515","article-title":"Interferon-complement loop in transplant-associated thrombotic microangiopathy","volume":"4","author":"Jodele","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.026_bib0020","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.026_bib0021","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.bbmt.2017.08.019","article-title":"Thrombotic microangiopathy after allogeneic stem cell transplantation: a comparison of eculizumab therapy and conventional therapy","volume":"23","author":"Bohl","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.026_bib0022","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC","volume":"99","author":"de Fontbrune","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2026.04.026_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.761726","article-title":"use of eculizumab in pediatric patients with transplant associated thrombotic microangiopathy","volume":"9","author":"Gomez-Ganda","year":"2021","journal-title":"Front Pediatr"},{"issue":"13","key":"10.1016\/j.jtct.2026.04.026_bib0024","first-page":"1049","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.026_bib0025","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1182\/bloodadvances.2023011078","article-title":"Pediatric transplant-associated thrombotic microangiopathy health care utilization and implications of eculizumab therapy","volume":"8","author":"Schoettler","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.026_bib0026","doi-asserted-by":"crossref","first-page":"929.e1","DOI":"10.1016\/j.jtct.2024.06.017","article-title":"Real-world application of recently proposed ASTCT\/CIBMTR\/EBMT\/APBMT consensus risk stratification for transplantation-associated thrombotic microangiopathy in children","volume":"30","author":"Schoettler","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.026_bib0027","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/bmt.2017.119","article-title":"Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD","volume":"52","author":"Zeisbrich","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"10.1016\/j.jtct.2026.04.026_bib0028","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1200\/JCO.21.02389","article-title":"Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy","volume":"40","author":"Khaled","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.026_bib0029","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood.2023022526","article-title":"A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation\u2013associated TMA","volume":"143","author":"Jodele","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.026_bib0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41409-022-01852-x","article-title":"Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study","volume":"58","author":"Svec","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.026_bib0031","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.026_bib0032","doi-asserted-by":"crossref","first-page":"601.e1","DOI":"10.1016\/j.jtct.2024.03.019","volume":"30","author":"Ben\u00edtez Carabante","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.026_bib0033","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/01.tp.0000230373.82376.46","article-title":"Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Uderzo","year":"2006","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.026_bib0034","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/bmt.2016.351","article-title":"Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation","volume":"52","author":"Yeates","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.026_bib0035","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.bbmt.2018.10.015","article-title":"Transplant-Associated Thrombotic Microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal","volume":"25","author":"Li","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.026_bib0036","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/bmt.2016.87","article-title":"Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy","volume":"51","author":"Vasu","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.026_bib0037","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ejh.13127","article-title":"Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients","volume":"101","author":"Rudoni","year":"2018","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.026_bib0038","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1111\/trf.15534","article-title":"Approaching treatment of transplant-associated thrombotic microangiopathy from two directions with eculizumab and transitioning from tacrolimus to sirolimus","volume":"59","author":"Jan","year":"2019","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.026_bib0039","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.bmt.1705454","article-title":"Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease","volume":"38","author":"Wolff","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.026_bib0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.026_bib0041","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jtct.2025.05.028","article-title":"An ASTCT, CIBMTR, EBMT, and APBMT consensus statement defining response criteria for hematopoietic cell transplantation associated thrombotic microangiopathy (TA-TMA) directed therapy: consensus response criteria for TA-TMA","volume":"31","author":"Schoettler","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.026_bib0042","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/ajh.70022","article-title":"Eculizumab is associated with increased infection rates and infection related mortality in children with thrombotic microangiopathy after HCT","volume":"100","author":"Schoettler","year":"2025","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.026_bib0043","doi-asserted-by":"crossref","first-page":"503.e1","DOI":"10.1016\/j.jtct.2025.11.037","article-title":"Outcomes of terminal complement blockade in adults with high-risk transplant-associated thrombotic microangiopathy: a comparative analysis","volume":"32","author":"Alhomoud","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.026_bib0044","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"53","author":"Corbacioglu","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.026_bib0045","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/bjh.16557","article-title":"Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS\/VOD after haematopoietic cell transplantation","volume":"190","author":"Cairo","year":"2020","journal-title":"Br J Haematol"},{"issue":"25","key":"10.1016\/j.jtct.2026.04.026_bib0046","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1182\/blood-2018-01-822957","article-title":"MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD","volume":"131","author":"Major-Monfried","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.04.026_bib0047","series-title":"Paper presented at: European Hematology Association","article-title":"Ravulizumab plus best supportive care to treat pediatric patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy: first results from a phase 3 trial","year":"2025"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.026_bib0048","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1016\/j.jtct.2024.01.031","article-title":"Eculizumab treatment outcomes in patients with allogeneic hematopoietic cell transplant (alloHCT)-associated thrombotic microangiopathy (TA-TMA): a retrospective single-center experience","volume":"30","author":"Samara","year":"2024","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:38:11Z","timestamp":1783211891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726003131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666636726003131"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.026","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eculizumab for Pediatric Hematopoietic Cell Transplant\u2013Associated Thrombotic Microangiopathy: Real-World Response Rates, Predictors of Poor Response, and an Optimal Time Point for Treatment Response Assessment","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}